吲哒帕胺抗高血压疗效及安全性观察

目的　评价吲哒帕胺缓释片 (1 5mg)对轻、中度高血压病人降压有效性及安全性。方法　采用双盲、随机对照的研究方法。经过 2周安慰剂洗脱期后 ,4 8例服吲哒帕胺缓释片 1 5mg ,4 6例服吲哒帕胺普通片 2 5mg ,每日一次。在安慰剂期末及治疗 2、4、6、8周末测坐位收缩压、舒张压及心率。治疗前及 8周末检查 :血钾、钠、尿酸、肌酐、谷丙转氨酶及谷草转氨酶 ,心电图。结果　两组治疗后 2、4、6、8周血压较治疗前明显降低 (P <0 0 1) ,8周末两组降压总有效率分别为 70 8%及 73 9% ,组间对比差异无显著性 (P >0 0 5 )。吲哒帕胺缓释片组不良反应明显少于普通片组 ,血钾降低及血浆尿酸增高发生率低 ,与吲哒帕胺普通片比较有显著性差异 (P <0 0 5 )。两组血钠、肌酐、谷丙转氨酶及谷草转氨酶及心率变化在治疗前后无变化。结论　吲哒帕胺缓释片治疗轻、中度高血压与普通片比较 ,降压效果相当 ,耐受性好 ,副作用少 ,对心、肝、肾无明显毒性作用

Efficacy and Safety of Indapamide in Treatment of Essential Hypertension

Objective To evaluate the efficacy and safety of indapamide SR 1 5 mg in patients with mild to moderate essential hypertension Methods A double blind, randomized study was designed A 2 week washout period was followed by an 8 week double blind treatment period Forty eight patients received indapamide SR 1 5 mg, forty six patients received indapamide IR 2 5 mg, once daily SBP, DBP and HR were measured at run in 2,4,6 and 8 wks after treatment Serum potassium, sodium, creatinine, GTP, GOT and electrocardiography were examined Results The blood pressure significantly decreased after treatment with indapamide SR 1 5 mg and IR 2 5 mg and the response rates were 70 8%, 73 9%, no significant difference between the two treatment groups( P >0 05). The adverse events were significantly less in indapamide SR 1 5 mg than with indapamide IR 2 5 mg. The mean decrease in serum potassium and increased in uric acid were significantly less in SR 1 5 mg than IR 2 5 mg( P <0 05). No significant differences in serum sodium, creatinine, GTP, GOT before and after the treatment. Conclusion Indapamide SR 1 5 mg is as effective as, much more tolerable than IR 2 5 mg in patients with mild to moderate essential hypertension.